Published in Nat Rev Clin Oncol on November 02, 2010
MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1. Nat Commun (2013) 1.76
Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta (2014) 1.53
Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol (2012) 1.45
miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer (2011) 1.44
miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J Biol Chem (2012) 1.39
MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis (2013) 1.37
MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. J Biol Chem (2011) 1.36
Circulating microRNAs as biomarkers, therapeutic targets, and signaling molecules. Sensors (Basel) (2012) 1.15
Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. Int J Biol Sci (2012) 1.14
EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours. Sci Rep (2012) 1.10
MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. J Clin Invest (2014) 1.09
NF-κB-dependent microRNA-125b up-regulation promotes cell survival by targeting p38α upon ultraviolet radiation. J Biol Chem (2012) 1.07
Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma. Clin Exp Metastasis (2013) 1.00
A microRNA signature associated with early recurrence in breast cancer. PLoS One (2014) 1.00
MicroRNAs: exploring a new dimension in the pathogenesis of kidney cancer. BMC Med (2010) 1.00
Tumor suppressor microRNA-27a in colorectal carcinogenesis and progression by targeting SGPP1 and Smad2. PLoS One (2014) 0.99
SRF expedites metastasis and modulates the epithelial to mesenchymal transition by regulating miR-199a-5p expression in human gastric cancer. Cell Death Differ (2014) 0.98
Transcriptional regulation of miR-196b by ETS2 in gastric cancer cells. Carcinogenesis (2012) 0.98
The molecular biology of brain metastasis. J Oncol (2012) 0.96
MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis. Oncotarget (2015) 0.94
Therapeutic Opportunities for Targeting microRNAs in Cancer. Mol Cell Ther (2014) 0.94
miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets. Mol Cell Endocrinol (2015) 0.94
Silencing miR-21 sensitizes non-small cell lung cancer A549 cells to ionizing radiation through inhibition of PI3K/Akt. Biomed Res Int (2014) 0.93
A tumor-promoting mechanism mediated by retrotransposon-encoded reverse transcriptase is active in human transformed cell lines. Oncotarget (2013) 0.89
Pancreatic cancer diagnosis by free and exosomal miRNA. World J Gastrointest Pathophysiol (2013) 0.89
miR-204 targeting of Ankrd13A controls both mesenchymal neural crest and lens cell migration. PLoS One (2013) 0.86
Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells. Exp Cell Res (2011) 0.86
Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis. Mediators Inflamm (2014) 0.85
MicroRNA profiling in Muc2 knockout mice of colitis-associated cancer model reveals epigenetic alterations during chronic colitis malignant transformation. PLoS One (2014) 0.84
Differentially expressed miRNAs in Ewing sarcoma compared to mesenchymal stem cells: low miR-31 expression with effects on proliferation and invasion. PLoS One (2014) 0.84
Regulatory roles of LINE-1-encoded reverse transcriptase in cancer onset and progression. Oncotarget (2014) 0.82
MiR-215, an activator of the CTNNBIP1/β-catenin pathway, is a marker of poor prognosis in human glioma. Oncotarget (2015) 0.82
MicroRNA signatures as biomarkers and therapeutic target for CNS embryonal tumors: the pros and the cons. Int J Mol Sci (2014) 0.81
Reduced FAF1 Expression and Helicobacter Infection: Correlations with Clinicopathological Features in Gastric Cancer. Gastroenterol Res Pract (2012) 0.80
Post-transcriptional processing of genetic information and its relation to cancer. Biotech Histochem (2013) 0.80
PDGF-B-mediated downregulation of miR-21: new insights into PDGF signaling in glioblastoma. Hum Mol Genet (2012) 0.80
miR-155, identified as anti-metastatic by global miRNA profiling of a metastasis model, inhibits cancer cell extravasation and colonization in vivo and causes significant signaling alterations. Oncotarget (2015) 0.80
Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review). Int J Oncol (2016) 0.79
MiRNA-146b-5p upregulates migration and invasion of different Papillary Thyroid Carcinoma cells. BMC Cancer (2016) 0.79
MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients. Genom Data (2016) 0.78
miR-30c negatively regulates the migration and invasion by targeting the immediate early response protein 2 in SMMC-7721 and HepG2 cells. Am J Cancer Res (2015) 0.78
Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor. Mol Cell Endocrinol (2014) 0.78
MiR-200c promotes bladder cancer cell migration and invasion by directly targeting RECK. Onco Targets Ther (2016) 0.77
microRNA-based cancer cell reprogramming technology. Exp Ther Med (2012) 0.77
Diagnostic and prognostic accuracy of miR-21 in renal cell carcinoma: a systematic review protocol. BMJ Open (2016) 0.77
Neuropilin-1 is a receptor for extracellular miRNA and AGO2/miRNA complexes and mediates the internalization of miRNAs that modulate cell function. Oncotarget (2016) 0.76
POU2F2-oriented network promotes human gastric cancer metastasis. Gut (2015) 0.76
Down-regulation of TIMP2 by HIF-1α/miR-210/HIF-3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma. Hepatology (2016) 0.76
[MicroRNAs in B-cells and T-cells as regulators of inflammation]. Z Rheumatol (2011) 0.76
Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Mol Cancer (2017) 0.75
Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells. Oncotarget (2016) 0.75
Endothelin-1 promotes epithelial-mesenchymal transition in human chondrosarcoma cells by repressing miR-300. Oncotarget (2016) 0.75
miR-125b controls monocyte adaptation to inflammation through mitochondrial metabolism and dynamics. Blood (2016) 0.75
miRNA-21 as a novel therapeutic target in lung cancer. Lung Cancer (Auckl) (2016) 0.75
MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status. Oncotarget (2016) 0.75
MicroRNA-16 suppresses metastasis in an orthotopic, but not autochthonous, mouse model of soft tissue sarcoma. Dis Model Mech (2015) 0.75
Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an indicator of poor prognosis. Oncotarget (2016) 0.75
miRNA in Prostate Cancer: New Prospects for Old Challenges. EJIFCC (2014) 0.75
DNA damage-induced nuclear factor-kappa B activation and its roles in cancer progression. J Cancer Metastasis Treat (2017) 0.75
1,25D3 differentially suppresses bladder cancer cell migration and invasion through the induction of miR-101-3p. Oncotarget (2017) 0.75
Periostin promotes epithelial-mesenchymal transition via the MAPK/miR-381 axis in lung cancer. Oncotarget (2017) 0.75
Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasis. Int J Oncol (2017) 0.75
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 31.38
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 24.27
bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell (2003) 22.14
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature (2007) 21.53
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res (2004) 18.86
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res (2005) 18.58
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev (2008) 15.01
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods (2007) 13.94
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 13.20
LNA-mediated microRNA silencing in non-human primates. Nature (2008) 11.45
The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Curr Biol (2003) 11.23
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene (2007) 10.79
A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep (2008) 10.71
Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51
The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem (2008) 10.08
miR-21-mediated tumor growth. Oncogene (2006) 9.90
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol (2009) 8.63
Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell (2009) 8.33
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res (2008) 7.53
Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem (2007) 7.46
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res (2008) 7.45
Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A (2008) 6.89
MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem (2007) 6.88
Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene (2006) 6.61
miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell (2008) 6.59
miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol (2004) 6.44
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer (2006) 5.47
Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA (2007) 5.35
MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol (2008) 5.21
Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res (2007) 5.09
The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle (2008) 4.95
hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res (2008) 4.84
Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol (2010) 4.80
Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res (2007) 4.72
MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem (2008) 4.69
OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer (2007) 4.59
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer (2010) 4.53
MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol (2008) 4.45
Dicer is required for embryonic angiogenesis during mouse development. J Biol Chem (2004) 4.40
Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology (2008) 4.38
MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology (2009) 4.36
MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A (2008) 4.33
MicroRNAs modulate the angiogenic properties of HUVECs. Blood (2006) 4.31
MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One (2006) 4.29
Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem (2006) 4.15
Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A (2009) 4.00
Exploring a new twist on tumor metastasis. Cancer Res (2006) 3.96
MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A (2007) 3.92
A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol (2009) 3.59
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene (2009) 3.51
LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry (2004) 3.41
Loss of mir-146a function in hormone-refractory prostate cancer. RNA (2008) 3.35
MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol (2009) 3.29
MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet (2010) 3.12
Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer (2010) 3.11
miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep (2009) 3.03
miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One (2009) 2.97
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther (2009) 2.92
The role of microRNAs in cancer: no small matter. Eur J Cancer (2007) 2.85
Regression of murine lung tumors by the let-7 microRNA. Oncogene (2009) 2.83
Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood (2007) 2.83
Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res (2009) 2.80
Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem (2008) 2.75
miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol (2008) 2.61
The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol (2009) 2.56
Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer (2008) 2.53
Homeobox D10 induces phenotypic reversion of breast tumor cells in a three-dimensional culture model. Cancer Res (2005) 2.45
Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res (2009) 2.45
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Altered MicroRNA expression in cervical carcinomas. Clin Cancer Res (2008) 2.42
AngiomiRs--key regulators of angiogenesis. Curr Opin Genet Dev (2009) 2.40
microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood (2010) 2.37
MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer (2009) 2.36
MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res (2009) 2.33
Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res (2006) 2.32
microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res (2009) 2.32
Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res (2005) 2.30
MicroRNA-143 and -145 in colon cancer. DNA Cell Biol (2007) 2.24
Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci U S A (1999) 2.19
MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle (2010) 2.18
MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res (2009) 2.17
MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2009) 2.16
miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS One (2010) 2.15
MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med (2009) 2.12
MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer (2009) 2.06
MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer (2009) 1.99
MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol (2008) 1.90
PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation. Cancer Res (2002) 1.88
Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem (2008) 1.87
High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat (2008) 1.86
microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. Brain Res (2009) 1.76
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer (2010) 4.53
Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol (2010) 4.11
Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience. J Urol (2010) 2.48
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol (2007) 2.40
Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol (2011) 2.29
Beta-trace protein, cystatin C, beta(2)-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children. Clin Chem (2002) 2.17
Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? J Mol Med (Berl) (2005) 2.16
MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med (2009) 2.12
Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem (2010) 1.99
Comparison of eight computer programs for receiver-operating characteristic analysis. Clin Chem (2003) 1.96
In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol Biol (2007) 1.93
Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem (2006) 1.88
Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem (2009) 1.84
Matrix metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in serum do not reflect the analytes circulating in blood. Arterioscler Thromb Vasc Biol (2007) 1.83
Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol (2010) 1.82
Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur Urol (2008) 1.78
Informatics for practicing anatomical pathologists: marking a new era in pathology practice. Mod Pathol (2010) 1.73
Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Mol Cell Proteomics (2012) 1.72
Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies-experience at the Charité Hospital Berlin, Campus Mitte. Eur Urol (2006) 1.71
Impact of RNA degradation on gene expression profiling. BMC Med Genomics (2010) 1.67
Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer (2004) 1.66
Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer. J Urol (2006) 1.63
A bibliometric evaluation of publications in urological journals among European Union countries between 2000-2005. Eur Urol (2007) 1.62
miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol (2011) 1.61
Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms. Clin Chem (2011) 1.59
Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol (2002) 1.56
Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol (2010) 1.55
ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate (2003) 1.54
Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol (2005) 1.51
Influence of tibial slope asymmetry on femoral rotation in patients with lateral patellar instability. Knee Surg Sports Traumatol Arthrosc (2012) 1.50
The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J Urol (2010) 1.50
Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer (2010) 1.50
An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics. BJU Int (2008) 1.45
Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem (2002) 1.42
The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer. Tumour Biol (2005) 1.41
Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate (2004) 1.40
Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res (2011) 1.40
CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate (2004) 1.37
Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res (2008) 1.37
Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol (2003) 1.37
miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn (2013) 1.30
Personalized medicine: marking a new epoch in cancer patient management. Mol Cancer Res (2010) 1.28
Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol (2010) 1.28
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer (2008) 1.26
A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate (2009) 1.25
Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Anal Biochem (2011) 1.25
The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn (2012) 1.24
Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res (2006) 1.23
Metabolic profiling reveals key metabolic features of renal cell carcinoma. J Cell Mol Med (2011) 1.23
Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer (2010) 1.21
Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem (2012) 1.20
Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate (2003) 1.19
MicroRNAs and cancer: current state and future perspectives in urologic oncology. Urol Oncol (2008) 1.18
YouTube, dentistry, and dental education. J Dent Educ (2011) 1.18
Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. Int J Biol Sci (2012) 1.14
Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem (2012) 1.14
MicroRNAs as regulators of signal transduction in urological tumors. Clin Chem (2011) 1.14
Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem (2002) 1.13
Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses. Tumour Biol (2011) 1.13
Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. J Proteome Res (2009) 1.13
Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression. Int J Oncol (2008) 1.13
Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem (2006) 1.13
Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards. Clin Chem Lab Med (2008) 1.12
A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem (2006) 1.12
Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma. Oncotarget (2014) 1.11
Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer. Prostate (2006) 1.11
Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol (2004) 1.11
Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem (2003) 1.10
Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Exp Mol Med (2010) 1.10
Reference miRNAs for miRNAome analysis of urothelial carcinomas. PLoS One (2012) 1.09
Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate (2007) 1.09